GLP-1s like Semaglutide and Tirzepatide represents a novel approach to treating obesity. It falls under the category of GLP-1 Receptor Agonists and Incretin Mimetics, initially approved in 2017 for managing blood sugar in Type 2 Diabetes.

GLP-1s like Semaglutide and Tirzepatide, a GLP-1 agonist, not only regulates blood sugar but also contributes to weight loss. By slowing gastric emptying and inhibiting the release of glucagon, it reduces hunger, leading to decreased food intake and subsequent weight loss.

GLP-1s like Semaglutide and Tirzepatide have proven to be highly effective in clinical studies, leveraging the same receptors as naturally occurring GLP-1 hormones. This enhances metabolic function, regulates digestion, promotes a prolonged feeling of fullness, and maximizes nutrient absorption.

Commencing at 0.25mg, the injection dosage is gradually increased every 4 weeks or as directed by your provider.

GLP-1s like Semaglutide and Tirzepatide are administered as a weekly subcutaneous injection in the abdomen, alternating locations. Begin with a low dose and gradually increase, strictly following the recommended dosing schedule.

No, GLP-1s like Semaglutide and Tirzepatide are not insulin or a substitute for it. It stimulates insulin release but is not suitable for those with type 1 diabetes. Insulin regulation is advised under the supervision of a treating physician for individuals with type 1 diabetes.

Initiating at 0.25mg is intended to minimize adverse effects. Individual responses may vary.

No, GLP-1s like Semaglutide and Tirzepatide are non-stimulant and non-habit-forming. It can be used concurrently with appetite suppressants like phentermine or phendimetrazine.

Yes, GLP-1s like Semaglutide and Tirzepatide are believed to curb appetite by slowing gastric emptying and influencing appetite regulation through GLP-1.

No, GLP-1s like Semaglutide and Tirzepatide are not covered for non-diabetic individuals.

Weight loss may not be immediate; patience is essential. Some individuals only experience weight loss at higher doses, such as 1 mg or 2 mg.

Wait for at least 4 weeks before considering a dose increase. Adherence to the recommended dosing schedule is crucial to minimize side effects.

The response depends on the duration since the missed dose. Follow specific guidelines, ranging from continuing at the current dose to titrating back down and gradually back up.

Common side effects include diarrhea, constipation, low blood sugar, headache, dizziness, and fatigue. Consult a physician for side effects not listed.

Most gastrointestinal side effects are transient and occur early in treatment.

Immediate medical attention is necessary for signs of a thyroid tumor or if there’s a history of certain conditions. GLP-1s like Semaglutide and Tirzepatide are contraindicated for certain medical histories.

Animal studies indicate cases of thyroid tumors with GLP-1s like Semaglutide and Tirzepatide, but it’s unclear if these effects translate to humans.

Emergency medical attention is needed for allergic reactions, vision changes, mood changes, heart-related symptoms, signs of pancreatitis, gallbladder issues, and low blood sugar. Specific symptoms necessitate immediate attention.

Women of childbearing potential should use contraception during therapy. If pregnancy is desired, stop treatment at least 2 months prior due to a long washout period. Breastfeeding while using GLP-1s like Semaglutide and Tirzepatide is not recommended.

Low blood sugar symptoms can be managed with appropriate food intake. Various factors, such as stress, illness, or alcohol use, can affect blood sugar.

GLP-1s like Semaglutide and Tirzepatide may slow digestion and affect oral medications. Inform your doctor about all medicines, particularly those for diabetes. Avoid taking medications, including acetaminophen, one hour before the weekly injection.